MEDIMMUNE LIMITED
Company Information
- Company Number
- 02451177
- Registered Address
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA
- Status
- Active
- Employee Count
- 202
- Turnover
- £2,595,000,000
- EBITDA
- £968,000,000
Additional Details
- Website
- https://medimmune.com
- Company Type
- Private limited Company
- Incorporated On
- 11 December 1989
- Nature of Business
- 72190 - Other research and experimental development on natural sciences and engineering
- Industries
- Professional Services
- Region
- East of England
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 31 Jul 2025 | 52 | 2% | 97% | 1% | 0% |
| 01 Jul 2024 - 31 Dec 2024 | 14 Feb 2025 | 56 | 4% | 94% | 2% | 3% |
| 01 Jan 2024 - 30 Jun 2024 | 12 Jul 2024 | 57 | 3% | 95% | 2% | 4% |
| 01 Jul 2023 - 31 Dec 2023 | 23 Jan 2024 | 57 | 3% | 95% | 2% | 2% |
| 01 Jan 2023 - 30 Jun 2023 | 27 Jul 2023 | 56 | 4% | 94% | 2% | 6% |
| 01 Jan 2022 - 30 Jun 2022 | 28 Jul 2022 | 59 | 5% | 93% | 2% | 2% |
| 01 Jul 2021 - 31 Dec 2021 | 30 Jan 2022 | 48 | 37% | 51% | 12% | 4% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 53 | 14% | 79% | 7% | 3% |
| 01 Jan 2020 - 30 Jun 2020 | 29 Jul 2020 | 50 | 17% | 76% | 7% | 0% |
| 01 Jan 2019 - 30 Jun 2019 | 29 Jul 2019 | 56 | 17% | 66% | 17% | 1% |
| 01 Jan 2018 - 30 Jun 2018 | 23 Jul 2018 | 52 | 21% | 74% | 5% | 1% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Standard terms range from immediate payment to 120 days.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
120
Dispute Resolution Process
Invoices are matched on receipt and disputed invoices notified to the supplier. Disputes are managed directly with the supplier and resolved items are reprocessed. Disputes are resolved within the existing payment terms.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
MedImmune Limited is a British biotechnology company that specializes in the development and production of innovative medicines and vaccines. The company is a subsidiary of AstraZeneca, a global pharmaceutical company.
Founded in 1992, MedImmune has established itself as a leader in the biopharmaceutical industry with a strong focus on research and development. The company's sustainability program aims to reduce its environmental impact through initiatives such as energy efficiency, waste reduction, and sustainable packaging.
MedImmune's products and services include treatments for respiratory, autoimmune, and infectious diseases. The company's portfolio includes FluMist, a nasal spray influenza vaccine, and Synagis, a preventive treatment for respiratory syncytial virus (RSV) in infants and young children. MedImmune also offers biologics manufacturing services to other pharmaceutical companies.
The key people at MedImmune include Bahija Jallal, the Executive Vice President of AstraZeneca and the President of MedImmune, and Dr. Corey Nislow, the Vice President of BioPharmaceutical Development at MedImmune. These individuals are responsible for driving the company's strategic direction and overseeing its operations.
The company's registered office address is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom. Contact information for MedImmune can be found on their website, www.medimmune.com, where customers and partners can also learn more about the company's products and services. Overall, MedImmune Limited is committed to providing innovative and sustainable solutions for improving global health.
